Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

MORPHOSYS : to Present at Upcoming Investor Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/02/2011 | 04:05pm CEST

MorphoSys AG / MorphoSys to Present at Upcoming Investor Conference Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Chief Executive Officer Dr Simon Moroney will present at the upcoming Société Générale Healthcare and Biotechnology Conference in Paris.

 

Société Générale Healthcare and Biotechnology Conference
Date: February 9, 2011
Venue: Paris, France
Presenter: Dr. Simon Moroney, CEO of MorphoSys AG

 

A PDF version of the company presentation is provided at www.morphosys.com:
http://www.morphosys.com/

 

 

 

 

+++MorphoSys will publish its Full Year 2010 Results on February 24, 2011+++

 

 

About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/:
http://www.morphosys.com/

 

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys. arYlaTM is a trademark of MorphoSys.

 

 

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

 

 

 

 

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

 

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

 

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

 

[email protected]:
mailto:[email protected]

 

Press Release:
http://hugin.info/130295/R/1484742/419929.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


HUG#1484742


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
05:05pMORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
04:40pMORPHOSYS AG : Preliminary announcement of the publication of financial reports ..
EQ
04:40pMORPHOSYS AG : Preliminary announcement of the publication of quarterly reports ..
EQ
04/23MORPHOSYS AG : MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering..
AC
04/23MORPHOSYS : Announces Closing of Nasdaq IPO through an ADS Offering and Exercise..
PU
04/23MORPHOSYS : Announces Closing of Nasdaq IPO through an ADS Offering and Exercise..
EQ
04/23MORPHOSYS AG : Release according to Article 41 of the WpHG [the German Securitie..
EQ
04/23MORPHOSYS : Resolves a Capital Increase to Implement the Offering of 8,300,000 A..
AQ
04/20MORPHOSYS : Cancer biotech MorphoSys prices $208 million US offering at $25.04
AQ
04/19MORPHOSYS : raises $208M in NASDAQ listing
AQ
More news
News from SeekingAlpha
04/19MorphoSys prices IPO at $25.04 per ADS, trading commences today 
04/14SA STOCK TO WATCH : Netflix To The Rescue? 
04/07U.S. IPO WEEK AHEAD : Subscription Unicorn Zuora Kicks Off The Q2 IPO Market 
03/183 THINGS IN BIOTECH, MARCH 17 : Janssen's Bladder Breakthrough, MorphoSys' Alzhe.. 
03/13MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2017 Results - Earnings Call Trans.. 
Financials (€)
Sales 2018 32,5 M
EBIT 2018 -106 M
Net income 2018 -101 M
Finance 2018 167 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 71,9x
EV / Sales 2019 37,7x
Capitalization 2 507 M
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 87,4 €
Spread / Average Target 1,5%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Marc Cluzel Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG12.37%3 063
CELLTRION, INC.--.--%31 379
IQVIA HOLDINGS INC0.11%20 258
LONZA GROUP-7.06%18 717
INCYTE CORPORATION-27.75%14 493
NEKTAR THERAPEUTICS44.36%13 873